Leerink Partners analyst Puneet Souda maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) on November 28. The company’s shares closed yesterday at $4.71.
Souda covers the Healthcare sector, focusing on stocks such as 908 Devices, Illumina, and Bio-Techne. According to TipRanks, Souda has an average return of -8.7% and a 39.58% success rate on recommended stocks.
AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $24.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $13.08 and a one-year low of $3.87. Currently, AbCellera Biologics has an average volume of 1.61M.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year. Last month, Hansen Carl L. G., the CEO of ABCL bought 56,125.00 shares for a total of $151,537.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbCellera Biologics (ABCL) Company Description:
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
Read More on ABCL:
- AbCellera has $1B + in liquidity to execute on strategy beyond next 3 years
- AbCellera announces reorganization, reduction in workforce
- AbCellera director Montalbano buys 30K shares of company stock
- AbCellera participates in a conference call with Truist
- AbCellera downgraded to Hold at Benchmark on longer wait for significant events
